Your session is about to expire
← Back to Search
Cabozantinib + Pembrolizumab for Stomach Cancer
Study Summary
This trial is testing a new cancer drug combo to see if it's effective for people with stomach or throat cancer who haven't responded to other treatments.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been diagnosed with HIV.You are currently pregnant or breastfeeding.I have no allergies to pembrolizumab, cabozantinib, or similar medications.I do not have any uncontrolled illnesses.I have not received a live vaccine in the last 30 days.I have an active case of tuberculosis.I am currently taking blood thinners.I am currently on medication for an infection.I have not had another type of cancer in the past 3 years.I have had one treatment with a checkpoint inhibitor and my cancer progressed, or my PD-L1 score is below 10%.I can swallow pills.I haven't had chemotherapy in the last 2 weeks.I don't have any health issues that could affect the study's results or my participation.My MSI-High or dMMR tumor has worsened after immunotherapy.I've had at least one treatment for my cancer that didn't work or I couldn't tolerate, including drugs like platinum or fluoropyrimidine.My cancer cannot be removed by surgery.You are expected to live for at least 3 more months.I can take care of myself but might not be able to do heavy physical work.I have recently undergone radiation therapy.My cancer is confirmed as gastric or gastroesophageal adenocarcinoma.My cancer is a type of stomach cancer called squamous cell or undifferentiated.Your platelet count needs to be at least 60,000 per microliter of blood.You are expected to live for at least 3 more months.My cancer did not respond or I couldn't tolerate a treatment that included platinum or fluoropyrimidine.Side effects from my previous cancer treatment, except for hair loss, have not improved to mild or returned to normal.I haven't had cancer treatment in the last 2 weeks.I haven't taken any small molecule kinase inhibitors in the last 2 weeks.My brain metastases have been stable and untreated for at least 4 weeks.I am 18 years old or older.You need to have at least 1000 neutrophils per microliter of blood.I can take care of myself but might not be able to do heavy physical work.I have had pneumonitis treated with steroids or have it now.I am 18 years old or older.My cancer is confirmed to be gastric or gastroesophageal adenocarcinoma.My cancer progressed after one treatment with a checkpoint inhibitor.My organs and bone marrow are working well.I haven't had major surgery in the last 2 weeks or minor surgery in the last 10 days.You have a sufficient amount of white blood cells in your body, at least 2,000 per microliter.You cannot be taking any other experimental drugs.I have an immune system disorder or have been on steroids or immune-suppressing drugs recently.My cancer cannot be removed by surgery.I have been treated with cabozantinib before.You have an autoimmune disease that required treatment in the past two years.You have a medical condition that could make it unsafe for you to participate in the study.
- Group 1: Cabozantinib and Pembrolizumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
If a patient wanted to enroll today, would they be able to?
"The trial is currently active and looking for 20 patients at a single location, this is according to information found on clinicaltrials.gov. The study was first posted on February 4th, 2020 and was last updated on October 31st, 2020."
How many individuals are signed up to participate in this experiment?
"Yes, according to the information available on clinicaltrials.gov, this study is still recruiting patients. The trial was first posted on February 4th, 2020 and was most recently updated on October 31st, 2022. They are looking for a total of 20 participants at a single location."
What are some common conditions that Pembrolizumab is used to treat?
"Pembrolizumab is frequently used to treat melanoma that cannot be surgically removed. It is also approved for use in cases of microsatellite instability high and patients with a high risk of recurrence."
Could you give some historical context for Pembrolizumab's medical usage?
"Presently, there are 1108 clinical trials underway that involve pembrolizumab. Out of these active studies, 135 have reached Phase 3 testing. The majority of pembrolizumab trials are based in Houston, Texas; however, 43129 medical facilities across the globe are running similar tests."
Has Pembrolizumab been cleared by the FDA?
"While there is some data supporting the safety of Pembrolizumab, it only exists for phase 2 trials. This means that its efficacy has not been studied and thus cannot be vouched for."
Share this study with friends
Copy Link
Messenger